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The human EpsteineBarr virus (EBV) evades the immune system by entering a transcriptionally latent
phase in B cells. EBV in tumor cells expresses distinct patterns of genes referred to as latency types.
Viruses in tumor cells also display varying levels of lytic transcription resulting from spontaneous
reactivation out of latency. We measured this dynamic range of lytic transcription with RNA deep
sequencing and observed no correlation with EBV latency types among genetically different viruses, but
type I cell lines reveal more spontaneous reactivation than isogenic type III cultures. We further deter-
mined that latency type and spontaneous reactivation levels predict the relative amount of induced
reactivation generated by cytotoxic chemotherapy drugs. Our work has potential implications for
personalizing medicine against EBV-transformed malignancies. Identifying latency type or measuring
spontaneous reactivation may provide predictive power in treatment contexts where viral production
should be either avoided or coerced.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The human EpsteineBarr virus (EBV) generates a global health
burden. This lymphotrophic DNA herpesvirus evades the immune
system by entering a latent phase in B cells that persists for life.
Compared to lytic replication, during which about a hundred genes
are expressed to amplify virus, latency restricts transcription to
approximately a dozen or fewer genes [1]. EBV can immortalize B
cells in vitro [2]. EBV is also associated with Burkitt lymphoma,
Hodgkin lymphoma, nasopharyngeal carcinoma, gastric carcinoma,
and other malignancies in vivo [1]. The requirement of speciﬁc
latent genes for in vitro transformation strongly argues that viral
infection contributes to oncogenesis in vivo [3]. Indeed, persistent
infection correlates with ~1% of all cancer worldwide [4]. Detailed
analysis of viral transcription during latency forms the foundational
context for understanding how EBV interacts with cancer cells.logy and Immunology, 1650
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Inc. This is an open access article uLatent forms of EBV express different sets of genes partially
dependent on the developmental state of the cancer cell prior to
immortalization [1]. While many exceptions to the rule exist,
transcriptional programs generally stereotype to one of a few pat-
terns. Type I latency limits expression to EBNA1, the gene encoding
the DNA-binding protein responsible for latent replication and
segregation, the EBER non-coding RNAs, and the BamHI A rightward
transcript (BART) RNAs. Type III latency further includes other EBNA
isoforms and messages for the three LMP products. BHRF1 is
expressed under certain conditions [5,6].
Improving upon previous genomic technologies, RNA deep
sequencing (RNA-seq) methods have illuminated novel details of
viral transcription [7e12]. Increased sensitivity identiﬁed new
transcripts and splice variants. Examination of Burkitt lymphoma
cell lines uncovered both latent and lytic gene expression [7,8,11].
Lymphoblastoid cell lines (LCLs) display a wide range of sponta-
neous reactivation [9]. We asked if the dynamic range of lytic
transcription in cell culture lines correlated with different EBV la-
tency types. We further use measurement of spontaneous reac-
tivation by RNA-seq to predict the induction response to cytotoxic
chemotherapy drugs. Our work may have implications for
personalizing medicine against EBV-transformed malignancies.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Deep sequencing of EBV transcription in Raji and Daudi cell lines. The X axis
denotes nucleotide position and the Y axis denotes the number of counts per million
mapped reads. RNA signals with unambiguously assignable annotations are marked.
BHRF1, EBNA2, and LMP1 are latent transcripts labeled blue. One representative tran-
scriptome from independent replicates is shown.
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2.1. Cell culture
Wemaintained Burkitt lymphoma cell lines at 37 Cwith 5% CO2
(v/v) in RPMI-1640 media containing 25 mM HEPES and 10% (v/v)
fetal bovine serum. We maintained LCLs similarly except with 15%
(v/v) fetal bovine serum. MutuI [13] cells grew under standard
conditions [14]. Raji [15] (CCL-86) and Daudi [16] (CCL-213) cell
lines were obtained from ATCC (Manassas, VA). The GM12878 [17]
(GM12878) cell line was obtained from the Coriell Institute for
Medical Research (Camden, NJ). Jeffery T. Sample (Pennsylvania
State University) provided the KemI and KemIII [18] cell lines,
Andrew I. Bell (University of Birmingham) provided the RaeI [19]
cell line, and Bill Sugden (University of Wisconsin, Madison) pro-
vided the 721 LCL [20]. We generated MutuIII by prolonged
passaging of MutuI in cell culture [13].
2.2. RNA-seq
We isolated RNA from 4 106 log phase cells homogenized with
a QIAshredder spin column (Qiagen). Total RNA was puriﬁed by
silica-based membrane afﬁnity as packaged in the RNeasy Mini Kit
(Qiagen). Preparations included the optional DNAse treatment step.
Single primer isothermal linear ampliﬁcation to cDNA [21] was
achieved using the Ovation RNA-Seq System V2 (NuGEN) and 20 ng
of RNA. 3 mg of cDNA was then sheared in a 40 mL volume using a
Covaris S2 Focused-ultrasonicator. We prepared deep sequencing
libraries by adaptor-mediated ampliﬁcation [22] as packaged in
either the Encore NGS Library System I (NuGEN) or Ovation Ultra-
low Library System V2 (NuGEN).
Each library was sequenced on a HiSeq (Illumina). 50 bp reads
were mapped using Bowtie [23] to an index containing both the
human hg19 and EBV reference [GenBank ID: NC_007605.1] ge-
nomes. Parameters allowed for up to two mismatches and only
considered reads that mapped to a unique sequence. The number of
hits at each base was counted and then normalized per million
mapped reads. RNA-seq proﬁling for every cell line was performed
with two or three biological replicates and yielded ~30e100million
mapped sequences each experiment with reproducible tran-
scriptome proﬁles.
2.3. Viral reactivation
We induced lytic replication of EBV with chemicals [14] and
measured reactivation by staining for the immediate-early lytic
transactivator BZLF1 using the paraformaldehyde-methanol
method [24] with a BZ1 antibody (Santa Cruz Biotechnology) and
goat anti-mouse IgG-FITC (Santa Cruz Biotechnology). Cells were
treated for three days with 100 mM bendamustine (SigmaeAldrich
or Millipore), 1 mg/mL gemcitabine (SigmaeAldrich), or 20 nM
romidepsin (Selleck Chemicals).
3. Results
3.1. Dynamic range of spontaneous reactivation
We began by asking what a strictly latent EBV transcriptome
looks like as measured by RNA-seq. To do so we examined the Raji
[15] and Daudi [16] cell lines, which adopt latency type III and I,
respectively. Both express very few viral gene products either
spontaneously or in response to stimuli: these lines contain little
early antigen under basal conditions, chemical treatment only
weakly increases early antigen production, and chemical treatment
cannot generate viral capsid antigen production [25,26]. By theabove metrics, Raji cells are generally more latent than Daudi cells.
Mechanistically, Raji genomes have a deletion in the BALF2 gene
necessary for progression through lytic replication [27]. Daudi ge-
nomes have deletions in other genes [28], although the source of
the lytic replication defect is less understood. Both Raji and Daudi
transcriptomes predominantly consist of signals from latent genes
(Fig. 1). Identiﬁed Raji transcripts include EBNA2, BHRF1, and LMP1.
Other overlapping EBNA exons are also expressed. In Daudi cells,
the strongest signal is the BHRF1 message. Our results resemble
analysis performed by others with the same lines [11]. Signals from
lytic gene expression generally peak at ~0e2 counts per million
mapped reads. These proﬁles act as a baseline for deﬁning a latent
transcriptome.
Cell lines with the same latency type display a broad range of
spontaneous reactivation. We measured the transcriptomes of
MutuI, KemI, and RaeI cells as a sampling of type I latency lines
(Fig. 2). In agreement with previously published data [7], we
detected widespread lytic transcription in the MutuI line. BHLF1
displays the strongest signal. Initiation of lytic DNA replication re-
quires transcription of this gene [29] and its expression level cor-
relates with spontaneous reactivation [9]. Other predominant
signals correspond to lytic transcripts as well. The KemI expression
proﬁle is similar: BHLF1 displays the strongest signal amidst many
lytic transcripts. The RaeI line, however, contrasts signiﬁcantly and
does not reveal lytic transcription on the same scale. The only
notable signals consist of BHRF1 and the BARTs. Trace levels of lytic
gene expression resemble amounts observed with Raji and Daudi
cells. RaeI transcriptomes therefore also reﬂect the more latent end
of the dynamic range of spontaneous reactivation.
Type III latency lines display variability of spontaneous reac-
tivation similar to type I lines (Fig. 2). The GM12878 LCL reveals a
pattern consisting of the strong BHLF1 signal and other lytic genes.
Signiﬁcant levels of latent transcripts, such as LMP1 and the 50 end
of the EBNA message from the C promoter, are also observed. The
721 LCL, KemIII, and MutuIII lines, however, predominantly express
latent transcripts such as EBNA messages, BHRF1, and LMP1. We
were reluctant to apply quantitative metrics previously used to
compare lyticness, such as percentage of viral compared to human
reads, or strength of the BHLF1 signal, to rank the lines we studied.
While those approaches work when comparing transcriptomes
with similar proﬁles and the same sequence [9], different levels of
latent gene expression between viruses with different sequences
confound analysis. We ﬁnd that visual inspection, qualitatively
comparing signals from latent and lytic genes, proves informative.
Because of the large variability in levels of spontaneous reactivation
within each latency type, bulk comparison of type I and type III
lines does not illuminate any general trend between latency type
Fig. 2. Deep sequencing of EBV transcription in latency I and latency III cell lines. The X
axis denotes nucleotide position and the Y axis denotes the number of counts per
million mapped reads. RNA signals with unambiguously assignable annotations are
marked. BHRF1, the BARTs, Cp, EBNA2, and LMP1 are latent transcripts labeled blue; all
others are lytic transcripts labeled red. One representative transcriptome from inde-
pendent replicates is shown.
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3.2. Latency type predicts spontaneous reactivation
Cell lines with type I latency undergo higher levels of sponta-
neous lytic transcription as measured by RNA-seq compared to
isogenic type III cultures. Genetic differences in both the host and
virus confound general comparisons between latency types using a
hodgepodge of cell lines. We therefore chose two sets of isogenic
pairs for detailed study. We derived the MutuIII line from MutuI
cells in culture [13]. While the MutuI transcriptomemostly consists
of signals from lytic genes, MutuIII predominantly reveals latent
transcripts (Fig. 2). The KemI and KemIII lines were both obtained
from the same tumor and yet adopt different latency programs [18].
The same relative difference holds as observed with the Mutu cell
lines: the KemI transcriptome is more lytic than the KemIII tran-
scriptome (Fig. 2). The dynamic range of spontaneous reactivation
between different lines of the same latency program is vast (Fig. 2),
therefore a randomly selected type I line may yield either more or
less lytic transcription when compared to a non-isogenic type III
line. When comparing isogenic pairs with RNA-seq proﬁling,
however, type I lines reveal more spontaneous reactivation thanthe matched type III line.
3.3. Spontaneous reactivation predicts induction levels
Perturbation with cytotoxic chemotherapy agents induces
greater lytic reactivation in type I latency lines with higher spon-
taneous reactivation levels compared to isogenic type III cultures.
We suspected that the biochemical mechanism allowing for more
spontaneous reactivation would also permit greater lytic induction
upon chemical treatment. DNA damaging agents and chromatin
modiﬁers such as the alkylator bendamustine [14], the nucleoside
analog gemcitabine [30], and the histone deacetylase inhibitor
romidepsin [31] disrupt EBV latency. Incubation of MutuI cells with
bendamustine, gemcitabine, and romidepsin readily induces lytic
reactivation as measured by increased expression of the BZLF1
immediate early protein (Fig. 3). Although we detect BZLF1 in less
than 1% of untreated cells, ~20e40% of treated cells stain positively
by ﬂow cytometry. Parallel treatment of MutuIII cells yields much
less or no reactivation. Only 0e2% of both treated and untreated
cells stain positively. A similar, though less stark, contrast is seen
between Kem lines. Incubation of KemI cells with romidepsin
moderately increases lytic reactivation from 0% in untreated cells to
6% in treated cells. KemIII cells yield no signiﬁcant increase be-
tween 1 and 2% of positively staining cells (Fig. 4). We unfortu-
nately could not obtain parallel data with bendamustine and
gemcitabine because both Kem lines were resistant to induction by
those chemicals. The trend observed for latency reversing agents
with which we have data, however, is consistent: type I lines yield
greater amounts of induced reactivation compared to the isogenic
type III line upon drug treatment. Because isogenic type I cell lines
display both more spontaneous reactivation and more induced
reactivation when compared to matched type III lines, the levels of
lytic transcription under spontaneous and induced conditions
correlate. Relative spontaneous reactivation measured with RNA-
seq therefore also predicts relative amounts of induced reac-
tivation in isogenic lines.
4. Discussion
The biochemical basis of spontaneous reactivation in EBV lends
the system to prediction of input/output behavior. Expression of
the immediate early gene BZLF1 initiates a transcriptional cascade
that results in the activation of lytic genes to assemble new viral
particles [32]. Small amounts of abortive replication, an incomplete
cascade, are detectable by RNA-seq of LCLs [9]. Different
biochemical events generate stochastic gene expression [33]. We
do not formally know if spontaneous lytic transcription results
from intrinsic noise, such as gene-, network-, and cell-level vari-
ability that activates the BZLF1 promoter, or from environmental
stimuli triggering signaling events sensed by EBV under physio-
logical conditions. Levels of spontaneous reactivation in LCLs
oscillate periodically [34]. Because cyclical processes suggest the
presence of a changing stimulus, we suspect that spontaneous lytic
transcription results from signaling events. If true, then under equal
environmental conditions for two cell lines, greater levels of
spontaneous reactivation in one line may reﬂect greater respon-
siveness of that EBV transcriptional network to the current stim-
ulus. That greater responsivenessmay be leveraged upon treatment
with small molecules known to reactive virus. We sought to test,
and argue that we have veriﬁed, this hypothesis.
The ability to predict the extent of induced reactivation in EBV-
containing tumor cells may inform clinical strategies to cure cancer.
Lytic induction therapy attempts to generate replicating virus to
serve as targets for immune responses or antiviral drugs [35]. Un-
fortunately, we currently know of fewmolecular markers to predict
Fig. 3. EBV reactivation in MutuI and MutuIII cells induced by bendamustine, gemcitabine, and romidepsin. BZLF1 expression was measured by ﬂow cytometry. Error bars represent
the standard deviation of n ¼ 4 replicates.
Fig. 4. EBV reactivation in KemI and KemIII cells induced by romidepsin. BZLF1
expression was measured by ﬂow cytometry. Error bars represent the standard devi-
ation of n ¼ 4 replicates.
A.T. Phan et al. / Biochemical and Biophysical Research Communications 474 (2016) 71e7574the efﬁcacy of latency-disrupting agents. The viral LMP1 protein
suppresses reactivation by anti-IgM and phorbol esters [36]. Our
work advances predictive power in two practical ways. First,
comparing latency types focuses on a frequently observed
distinction between viruses in tumors; rarely does the transcrip-
tional difference between two isolates consist only of LMP1
expression. Indeed, both type I and type III latency occur in lym-
phomas with similar presentation [12]. Second, we examine cyto-
toxic chemotherapy drugs that are currently used to treat patients
with EBV-associated malignancies in the clinic. Although our
analysis only predicts differences in isogenic backgrounds, sug-
gesting that other factors confound comparisons, we identiﬁed
regulated molecular signatures of reactivation potential that add to
our understanding of this complex transition from latency.
Knowledge of potential lytic replication beneﬁts multiple contexts.
In some cases, reactivation should be avoided to reduce adverse
effects caused by increased viral load. In other cases, reactivation
would be desired to execute lytic induction therapy. Proﬁling viral
transcription may provide predictive power that could yield
tangible improvements in treatment decisions.Acknowledgements
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